Epilepsy & Seizures
News
FDA Approves Generic Vigabatrin for Complex Partial Seizures
Monday, January 21, 2019—January 21, 2019 -- The Food and Drug Administration (FDA) has approved generic vigabatrin 500 mg tablets for adjunctive treatment of patients with complex partial seizures, a…
FDA Clears First-in-Class NonEEG, Seizure-Monitoring, Wearable Device for Children
Tuesday, January 08, 2019—The Food and Drug Administration (FDA) has granted 510(k) clearance for a wearable smartband device (Embrace; Empatica, Boston, MA) to detect seizure activity in children age …
American Academy of Neurology Call for Uniformity in Brain Death Standards
Thursday, January 03, 2019—Noting that only 1 state, Nevada, has adopted legislation requiring use of medically accepted guidelines for determining brain death, the American Academy of Neurology (AAN) i…
Lower Starting Dose of Cenobamate Alleviates Side Effect of DRESS Syndrome
Friday, December 07, 2018—At the American Epilepsy Society annual meeting in New Orleans, LA, results were presented from a large phase 3 safety study of the investigational antiepileptic drug, cenobam…
Fenfluramine Reduces Seizure Frequency in Patients With Dravet Syndrome
Friday, December 07, 2018—Results of a second phase 3 trial (Study 1504) and an ongoing open-label extension study (Study 1503) of fenfluramine for treatment of patients with Dravet syndrome showed tha…
Brivaracetam Efficacy for Treating Acute Seizures in Epilepsy Monitoring Unit
Wednesday, December 05, 2018—At the American Epilepsy Society Annual Meeting in New Orleans, LA, data were presented from an open-label, randomized, parallel-group, active control study (NCT03021018) and …
Perampanel Has Long-Term Convulsive Seizure Freedom, Efficacy at Lower Dose, and Was Recently Approved for Children Age 4 to 12 Years
Wednesday, December 05, 2018—Recently approved for use in children, age 4 and up, monotherapy or adjunctive treatment with perampanel (Fycompa; Eisai, Woodcliff Lake, NJ) is approved for treatment of part…
Midazolam Nasal Spray Safety and Efficacy Results Reported
Tuesday, December 04, 2018—In results presented at the American Epilepsy Society’s annual meeting in New Orleans, LA, midazolam nasal spray (USL261; UCB, Atlanta, GA), a drug being investigated fo…
